Leveraging epigenetics to enhance the efficacy of immunotherapy
BACKGROUND: Epigenetic mechanisms regulate chromatin accessibility patterns that govern interaction of transcription machinery with genes and their cis-regulatory elements. Mutations that affect epigenetic mechanisms are common in cancer. Because epigenetic modifications are reversible many anticancer strategies targeting these mechanisms are currently under development and in clinical trials.
MAIN BODY: Here we review evidence suggesting that epigenetic therapeutics can deactivate immunosuppressive gene expression or reprogram tumor cells to activate antigen presentation mechanisms. In addition, the dysregulation of epigenetic mechanisms commonly observed in cancer may alter the immunogenicity of tumor cells and effectiveness of immunotherapies.
CONCLUSIONS: Therapeutics targeting epigenetic mechanisms may be helpful to counter immune evasion and improve the effectiveness of immunotherapies.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:13 |
|---|---|
| Enthalten in: |
Clinical epigenetics - 13(2021), 1 vom: 17. Mai, Seite 115 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Licht, Jonathan D [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
DNA methylation |
|---|
| Anmerkungen: |
Date Completed 24.01.2022 Date Revised 24.01.2022 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1186/s13148-021-01100-x |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM325525013 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM325525013 | ||
| 003 | DE-627 | ||
| 005 | 20231225192628.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1186/s13148-021-01100-x |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1085.xml |
| 035 | |a (DE-627)NLM325525013 | ||
| 035 | |a (NLM)34001289 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Licht, Jonathan D |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Leveraging epigenetics to enhance the efficacy of immunotherapy |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 24.01.2022 | ||
| 500 | |a Date Revised 24.01.2022 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a BACKGROUND: Epigenetic mechanisms regulate chromatin accessibility patterns that govern interaction of transcription machinery with genes and their cis-regulatory elements. Mutations that affect epigenetic mechanisms are common in cancer. Because epigenetic modifications are reversible many anticancer strategies targeting these mechanisms are currently under development and in clinical trials | ||
| 520 | |a MAIN BODY: Here we review evidence suggesting that epigenetic therapeutics can deactivate immunosuppressive gene expression or reprogram tumor cells to activate antigen presentation mechanisms. In addition, the dysregulation of epigenetic mechanisms commonly observed in cancer may alter the immunogenicity of tumor cells and effectiveness of immunotherapies | ||
| 520 | |a CONCLUSIONS: Therapeutics targeting epigenetic mechanisms may be helpful to counter immune evasion and improve the effectiveness of immunotherapies | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, N.I.H., Extramural | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a DNA methylation | |
| 650 | 4 | |a Epigenetic therapy | |
| 650 | 4 | |a Histone methyltransferase | |
| 650 | 4 | |a Immune evasion | |
| 650 | 4 | |a Immunotherapy | |
| 700 | 1 | |a Bennett, Richard L |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical epigenetics |d 2010 |g 13(2021), 1 vom: 17. Mai, Seite 115 |w (DE-627)NLM205276547 |x 1868-7083 |7 nnns |
| 773 | 1 | 8 | |g volume:13 |g year:2021 |g number:1 |g day:17 |g month:05 |g pages:115 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1186/s13148-021-01100-x |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 13 |j 2021 |e 1 |b 17 |c 05 |h 115 | ||